A study, by Michael Nauck and colleagues from Bad Lauterberg im Harz, Germany, suggests that taspoglutide (R1583), a long-acting (once-weekly) human glucagon-like peptide-1 (GLP-1) analogue, currently under investigation by Roche for the treatment of type 2 diabetes mellitus, may likewise promote modest weight loss (Diabetes Care)
Health Canada has stated that many generic medications are 45 to 90 per cent cheaper than the brand-name versions [Source: globalnews.ca/news/11826332/canada-approves-2nd-generic-version-semaglutide/]
The article notes semaglutide commonly causes nausea, vomiting, and delayed gastric emptying that persist for weeks after starting, while ivermectin can trigger nausea and abdominal discomfort in some patients
Compounded semaglutide can be purchased monthly or as part of a 3 month bundle
however, more research is needed in order to model and find a better optimization process for this route with changing parameters and conditions in search of large-scale production [22,23,24]
Common side effects include (listed alphabetically): Constipation Dizziness Dry mouth Headaches Insomnia (mostly due to the phentermine) Loss of taste Numbness or tingling in your arms and legs Some of the more serious side effects include (listed alphabetically): Birth defects (cleft lip/cleft palate) if taken while pregnant Blurry vision or not seeing as well (a side effect from topiramate) Mood changes, panic attacks, depression, suicidal thoughts Racing heart or slightly rapid heartbeat (a side effect from phentermine) You should mention the more serious side effects to your provider as soon as possible (for a full list of side effects, please visit the manufacturers website)
